| Abstract | Budd-Chiari syndrome (BCS) . Many patients with BCS harbour several prothrombotic disorders. . Liver disease blurs the diagnostic features of most prothrombotic disorders. . Myeloproliferative disease account for 50% of BCS patients. Their recognition largely relies on the assessment of V617F JAK2 mutation in peripheral blood. . Treatment for BCS consists of the successive implementation of anticoagulation, percutaneous angioplasty, transjugular intrahepatic shunt and last, liver transplantation. . Using this progressive treatment strategy, overall 5-year survival rates approaching 90% are currently achieved. Veno-occlusive disease/Sinusoidal obstruction syndrome (VOD/SOS) . VOD/SOS is produced by a toxic injury to sinusoidal endothelial cells. . Many chemotherapeutic agents can induce VOD/SOS. . Knowledge in the metabolic determinants of drug toxicity to sinusoidal endothelium has deepened. The translation of new knowledge into prevention and treatment of VOD/SOS still need clinical studies. . Reduced intensity myeloablative regimens have proved efficient in reducing the incidence of VOD/SOS. |
